Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma
Yi Lin(Mayo Clinic), Rui Wang(Sun Yat-sen University), Deepu Madduri(Johnson & Johnson (United States)), Mounzer Agha(Dana-Farber Cancer Institute), Myo Htut(City Of Hope National Medical Center), Adam D. Cohen(Penn Center for AIDS Research), Sundar Jagannath(Mount Sinai Hospital), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Mythili Koneru(Cooper Medical School of Rowan University), Nikhil C. Munshi(Dana-Farber Cancer Institute), Jesús G. Berdeja(Tennessee Oncology), Abhinav Deol(Wayne State University), Elizabeth O’Donnell(Harvard University), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Rocío Montes de(Johnson & Johnson (United States)), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Thomas Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Christopher del Corral(490 BioTech (United States)), Hao Zhao(Johnson & Johnson (United States)), Carolyn C. Jackson(Centro de Investigación del Cáncer), Dong Geng, Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k